ArticleIDCases2026
Severe acute respiratory distress syndrome due to
Article in IDCases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Melioidosis is endemic in more than 45 countries worldwide. Recent reports of locally acquired cases in previously unaffected regions, including the southern United States, highlight the expanding geographic range of Case description: A 31‑year‑old man with no prior medical history developed acute respiratory failure 24 h after returning from a 2‑week stay in Saudi Arabia, where he had twice been received symptomatic treatment for a flu‑like illness. Shortly after arriving in France, he experienced sudden dyspnea with rapid neurological deterioration. Prehospital evaluation revealed severe hypoxemia (SpO₂ 54% on room air), confusion, and bilateral crackles, requiring immediate intubation and mechanical ventilation. On admission to the intensive care unit (ICU), he presented with severe acute respiratory distress syndrome (ARDS) (PaO₂/FiO₂ ratio <50), profound metabolic acidosis (pH 6.9), septic shock requiring norepinephrine, and a Simplified Acute Physiology Score II (SAPS II) of 84. Laboratory tests showed neutropenia, marked systemic inflammation (C-reactive protein [CRP] 501 mg/L), acute kidney injury, hyponatremia, and elevated liver enzymes. Chest computed tomography (CT) demonstrated diffuse bilateral consolidations with ground‑glass opacities and a crazy‑paving pattern.Microbiological investigations identified Outcome: Fatal severe ARDS due to Conclusion: Clinicians should maintain a high index of suspicion for melioidosis, even in non-endemic regions, particularly in travelers returning from areas where the disease is emerging or under-recognized. Early recognition is essential given the potential for rapid progression and high mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.